Thus, liver cancer with high PD-L1 expression may have high glucose metabolism characteristics, and 18F-FDG PET/CT may help evaluate the expression of PD-L1 in patients with liver metastasis to guide immunotherapy. The gene discussed is CD274; the disease is liver cancer.